Association of Radiation and Neutrophil to Lymphocyte Ratio with Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombus

PURPOSE/OBJECTIVE(S)

Hepatocellular carcinoma (HCC) is increasing in incidence worldwide with up to 60% of patients found to have a portal vein tumor thrombus at diagnosis. Recent studies demonstrated that high neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival in patients with hepatocellular carcinoma. Whether NLR can predict survival after local therapy, such as radiation (RT), is currently unknown. We, therefore, reviewed the patient outcomes with special focus on the type of therapies received.

MATERIALS/METHODS

This study is a retrospective review of HCC patients with portal vein thrombus from a single institution diagnosed between 2010 and 2022. Follow up time was defined as time from diagnosis to death or last follow up visit. Cox regression models were used to analyze overall survival (OS) rates.

RESULTS

One-hundred and forty-five patients met inclusion criteria. Median follow-up time was 4 months [interquartile range (IQR): 1.7 - 13 months]. Median NLR at diagnosis was 3.5 (IQR: 2.2-4.9). Forty patients received RT as part of their therapy. Higher NLR was associated with shorter survival (HR 1.10, 95% CI 1.04 - 1.17, p = 0.002). Treatment with RT improved OS (HR 0.55, 95% CI 0.35 - 0.86, p = 0.009). After controlling for NLR at diagnosis, the addition of radiation still provides survival benefit (HR 0.55, 95% CI 0.35 - 0.86, p = 0.01). In patients who received immunotherapy as the first systemic agent, RT improved OS (HR 0.47, 95% CI 0.22 - 1.01, p = 0.05). This improvement held even when controlling for NLR. In patients who received tyrosine kinase inhibitor (TKI) as first systemic agent, RT did not improve OS. However, when controlling for NLR in patients receiving TKI, RT did improve OS (HR 0.45, 95% CI 0.2 - 1.0, p = 0.05).

CONCLUSION

This retrospective, hypothesis-generating analysis suggests that NLR at diagnosis could predict OS benefit of RT addition in certain patients. These results could be due to the effect of radiation on the immune system; however, further studies are needed.

Novel unconventional radiotherapy techniques: Current status and future perspectives - Report from the 2nd international radiation oncology online seminar

•Improvement of therapeutic ratio by novel unconventional radiotherapy approaches.•Immunomodulation using high-dose spatially fractionated radiotherapy.•Boosting radiation anti-tumor effects by adding an immune-mediated cell killing.

Repurposing Radiation Therapy for Immuno-oncology

Radiation therapy is traditionally used for the local control of tumour growth, but recent studies suggest that radiation therapy can have immunomodulatory properties that can be applied in combination therapy with immunotherapeutic agents. The paradigm of using radiation therapy for immunomodulation in cancer treatment is a rapidly progressing field, with multiple ongoing clinical trials exploring its use in combination with immune checkpoint blockades to induce an abscopal effect. Permutations of radiation therapy regimens, including variations in radiation dosing, radiation planning parameters and radiation modality, are being tested with varying degrees of success. The relative biological effectiveness was a concept introduced in the early days of radiation biology that allows the comparison of local tumour control across various radiation modalities and energies. Similarly, there remains a need for a new concept of comparing the immunological effectiveness of various radiation modalities. In this review, we will provide an overview of immunobiological models for preclinical and clinical monitoring of radiation therapy regimens and introduce the concept of relative immunological effectiveness to compare and screen for immune-activating functions of these regimens.

Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis

PURPOSE

Immunotherapy is now a first-line treatment for metastatic non-small cell lung cancer (NSCLC) and melanomaQuery. It is important to understand the relationship between immunotherapy and radiation to the brain. The aim of this study was to assess the role of stereotactic radiosurgery (SRS) or WBRT in addition to immunotherapy in patients with melanoma or NSCLC metastatic to the brain.

METHODS/PATIENTS

Using the National Cancer Database, 2951 patients with NSCLC and 936 patients with melanoma treated with immunotherapy were identified. Patients were classified as having received immunotherapy alone, immunotherapy with SRS, or immunotherapy with whole-brain radiation therapy (WBRT). Kaplan-Meier, multivariate Cox regression analyses, and propensity matching were performed to evaluate the impact of adding SRS to immunotherapy on overall survival (OS). Immortal survival bias was accounted for by only including patients who received radiation before immunotherapy and time zero was defined as the start of immunotherapy.

RESULTS

205(6.9%) and 75(8.0%) patients received immunotherapy with no radiation, 822(27.9%) and 326(34.8%) received SRS and immunotherapy, and 1924(65.2%) and 535(57.2%) received WBRT and immunotherapy for NSCLC and melanoma, respectively. Adding SRS to immunotherapy was associated with improved OS in multivariate analyses (NSCLC HR = 0.81, 95% CI 0.66-0.99, p = 0.044; melanoma HR = 0.63, 95% CI 0.45-0.90, p = 0.011). The addition of WBRT to immunotherapy did not improve OS in patients with melanoma nor NSCLC.

CONCLUSIONS

This analysis suggests that treatment with SRS and immunotherapy is associated with improved OS compared to immunotherapy alone for patients with melanoma or NSCLC metastatic to the brain.